Status: Active


  • Status Current
  • Sector Heart Failure
  • Year Invested 2020
  • HQ Baar, Zug, Switzerland
  • Clinical Operations Switzerland, Lithuania
  • Lead Partner Frederik Groenewegen


Diagnosis & Targeted Therapy of Microvascular Obstruction (MVO)

Developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. Microvascular obstruction (MVO) after an acute heart attack is documented to be an independent marker leading to costly complications such as Heart Failure. CorFlow may enable interventional cardiologists to treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complication rates in these patients.